Scholarlink

Purpose of Review <p>As greater emphasis is placed on survivorship and long-term morbidity, more attention is being paid to de-escalation. This review examines areas where radiation may be safely omitted without compromising outcomes, thereby improving quality of life for breast cancer survivors.</p> Recent Findings <p>Prospective randomized trials have identified populations that may safely avoid radiation after lumpectomy, although in many cases this may be a choice between radiation or anti-estrogen therapy. There is also retrospective and emerging prospective data identifying subsets of node positive patients undergoing mastectomy for whom radiation can be omitted, including low-risk patients and patients with complete responses to neoadjuvant therapy.</p> Summary <p>Several retrospective and prospective studies have demonstrated that for subsets of patients, often based on newer prognostic assays, radiation may be safely omitted. This often involves shared decision making with the patient in a multidisciplinary fashion, as de-escalation of one modality is often predicated on the receipt of others. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Reshaping Breast Cancer Survivorship Through Expanding the Indications for the Omission of Radiation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月11日

查看全文
  • Michael S. Sabel,
  • Elizabeth M. Jaworski

摘要

Purpose of Review

As greater emphasis is placed on survivorship and long-term morbidity, more attention is being paid to de-escalation. This review examines areas where radiation may be safely omitted without compromising outcomes, thereby improving quality of life for breast cancer survivors.

Recent Findings

Prospective randomized trials have identified populations that may safely avoid radiation after lumpectomy, although in many cases this may be a choice between radiation or anti-estrogen therapy. There is also retrospective and emerging prospective data identifying subsets of node positive patients undergoing mastectomy for whom radiation can be omitted, including low-risk patients and patients with complete responses to neoadjuvant therapy.

Summary

Several retrospective and prospective studies have demonstrated that for subsets of patients, often based on newer prognostic assays, radiation may be safely omitted. This often involves shared decision making with the patient in a multidisciplinary fashion, as de-escalation of one modality is often predicated on the receipt of others.